8-K: NeuroBo Pharmaceuticals Announces Positive Pre-Clinical Safety Data and Opens Enrollment for Phase 2a Trial of DA-1241

NeuroBo Pharmaceuticals reports positive pre-clinical safety data for DA-1241 in combination with sitagliptin and has opened enrollment for Part 2 of its Phase 2a clinical trial for MASH.

Summary

• NeuroBo Pharmaceuticals has announced positive pre-clinical safety data for its drug candidate DA-1241 when combined with sitagliptin.
• The pre-clinical study in rats showed that daily oral administration of DA-1241, sitagliptin, or the combination was well tolerated with no adverse effects over 13 weeks.
• The company has also opened enrollment for Part 2 of its Phase 2a clinical trial of DA-1241 in combination with sitagliptin for the treatment of MASH.
• Part 2 of the trial is expected to enroll approximately 37 subjects, randomized into two groups: DA-1241 with sitagliptin, or placebo.
• The primary endpoint for both Part 1 and Part 2 of the trial is the change from baseline in alanine transaminase (ALT) levels at Week 16.
• The full data readout from Part 2 of the trial is expected in the second half of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful pre-clinical safety data and the progression of the clinical trial. The language used is optimistic and highlights the potential of DA-1241.

Positives

• Pre-clinical studies showed that DA-1241, both alone and in combination with sitagliptin, was well tolerated with no adverse effects.
• DA-1241 has shown to improve both hepatic and systemic inflammation.
• The combination of DA-1241 with sitagliptin increased anti-inflammatory effects compared to DA-1241 alone.
• DA-1241 was also well tolerated in healthy volunteers and patients with type 2 diabetes in previous trials.
• The company has met its 45-day commitment with the FDA, allowing the Phase 2a trial to progress.

Risks

• The success of the clinical trials is not guaranteed, and results may not be consistent with pre-clinical data.
• There are risks associated with the development of new pharmaceutical products, including regulatory hurdles and potential negative interactions with other products.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to various risks and uncertainties.
• The company's financial position and stock price could be impacted by the results of the clinical trials and the progress of the drug development.

Future Outlook

The company expects to report the full data from the Part 2 trial in the second half of 2024.

Management Comments

• Initiating Part 2 of our clinical study of DA-1241 in MASH patients paves the way to begin dosing in combination with sitagliptin, marking another significant clinical milestone for our most advanced asset, stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo.
• Based on the pre-clinical evidence to date, DA-1241 has been shown to improve both hepatic and systemic inflammation effectively, and the combination with sitagliptin increased the anti-inflammatory effects compared to DA-1241 as a monotherapy.

Industry Context

The development of DA-1241 targets the growing market for treatments for MASH and T2DM, which are significant health concerns globally. The combination therapy approach with a GPR119 agonist and a DPP4 inhibitor is a novel approach in this space.

Comparison to Industry Standards

• The pre-clinical safety results of DA-1241 in combination with sitagliptin are comparable to other early-stage studies of similar drug candidates in the MASH and T2DM space.
• The Phase 2a trial design, with its randomized, double-blind, placebo-controlled approach, is consistent with industry standards for clinical trials in this therapeutic area.
• Companies like Madrigal Pharmaceuticals and Intercept Pharmaceuticals have also been developing treatments for MASH, and NeuroBo's progress will be closely watched in comparison to these competitors.
• The use of ALT levels as a primary endpoint is a common practice in MASH clinical trials, aligning with industry benchmarks.

Stakeholder Impact

• Shareholders will be encouraged by the positive pre-clinical data and the progress of the clinical trial.
• Patients with MASH may benefit from the development of a new treatment option.
• Employees of NeuroBo will be involved in the ongoing clinical trial and drug development process.

Next Steps

• The company will continue enrollment for Part 2 of the Phase 2a clinical trial.
• The company will monitor the safety and efficacy of DA-1241 in the ongoing clinical trial.
• The company expects to report the full data from the Part 2 trial in the second half of 2024.

Key Dates

Keywords

DA-1241, MASH, sitagliptin, GPR119 agonist, clinical trial, pre-clinical, DPP4 inhibitor, metabolic dysfunction, Phase 2a, safety data